Blood News and Research

RSS

KRISS develops ultra-sensitive platform to detect Alzheimer’s biomarkers in body fluids

The Korea Research Institute of Standards and Science (KRISS, President Lee Ho Seong) has developed a diagnostic platform that amplifies the unique optical signals of molecules by more than a hundred million times, enabling the precise detection and quantification of trace amounts of Alzheimer's disease biomarkers in body fluids.

1 Sep 2025

$New hypothesis links internal fat biology to heart failure with preserved ejection fraction$

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of understanding how fat may impact the heart.

1 Sep 2025

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

1 Sep 2025

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of patients with myocardial infarction (MI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Triglyceride levels substantially reduced with olezarsen compared to placebo

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance.

1 Sep 2025

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak oxygen consumption compared with placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Diabetes drug metformin alters blood metal levels in humans

The widely used diabetes drug metformin changes blood metal levels in humans. The Kobe University study is an important step in understanding the drug's many actions and designing better ones in the future.

1 Sep 2025

Can oral bacteria make heart disease worse?

The presence of viridans streptococci in coronary plaques indicates a role in atherosclerosis, potentially influencing heart disease outcomes.

1 Sep 2025

Babies fed blueberries show fewer allergy symptoms and boosted immune balance

Daily blueberry powder given to infants during complementary feeding modestly influenced allergic symptom resolution and shaped immune biomarker–microbiota associations. Findings suggest early diet may play a role in immune development, though results are preliminary and exploratory.

31 Aug 2025

How plant compounds could target Alzheimer’s disease from multiple angles

This review highlights how dietary polyphenols modulate Alzheimer’s disease biology through antioxidant, anti-inflammatory, and multi-target mechanisms, supported by in-silico docking analyses. Despite promise, challenges in bioavailability and brain delivery remain key hurdles to clinical translation.

31 Aug 2025

Ultra-processed foods affect sperm quality and metabolism even without extra calories

A controlled crossover trial in Cell Metabolism found that ultra-processed foods increase weight, fat mass, LDL:HDL cholesterol, and alter reproductive hormones in men, with some effects independent of calorie load. These diets also showed trends toward reduced sperm motility, shifts in pollutants, and transient inflammatory responses, highlighting risks beyond excess calories.

31 Aug 2025

New ESC guidelines introduce unified approach to improve myocarditis and pericarditis care

New ESC Guidelines to improve the diagnosis and care of patients with myocarditis and pericarditis, have been published today at ESC Congress 2025.

30 Aug 2025

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC/EAS Focused Update to Guidelines, about how best to manage lipid levels in patients to reduce cardiovascular risk, recommends the use of new cardiovascular risk predication algorithms. The update was published today at ESC Congress 2025.

30 Aug 2025

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

Updated ESC Guidelines, published today at ESC Congress 2025, put a focus on a woman's autonomy in making her own reproductive choices by promoting a transparent dialogue and shared decision-making for pregnancies that are high-risk for an adverse maternal and/or fetal event.

30 Aug 2025

Insights into clinical features and genetic variants of Cornelia de Lange syndrome in China

Cornelia de Lange syndrome (CdLS) is a rare genetic disorder with symptoms, including facial anomalies (such as fused eyebrows, short nose, upturned nose tip, and downturned mouth corners), growth retardation, small head (microcephaly), developmental delays, cognitive impairments, excess hair growth, and limb anomalies.

29 Aug 2025

Many preschoolers with ADHD receive medication before behavioral therapy

Young children with attention deficit/hyperactivity disorder often receive medication just after being diagnosed, which contravenes treatment guidelines endorsed by the American Academy of Pediatrics, a Stanford Medicine-led study has found.

29 Aug 2025

Blood News and Research

KRISS develops ultra-sensitive platform to detect Alzheimer’s biomarkers in body fluids

New hypothesis links internal fat biology to heart failure with preserved ejection fraction

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

Shorter dual antiplatelet therapy may offer safety benefits in myocardial infarction patients

Triglyceride levels substantially reduced with olezarsen compared to placebo

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Diabetes drug metformin alters blood metal levels in humans

Can oral bacteria make heart disease worse?

Babies fed blueberries show fewer allergy symptoms and boosted immune balance

How plant compounds could target Alzheimer’s disease from multiple angles

Ultra-processed foods affect sperm quality and metabolism even without extra calories

New ESC guidelines introduce unified approach to improve myocarditis and pericarditis care

ESC releases new guidance on lipid management to reduce cardiovascular risk

New ESC guidelines prioritize women's autonomy in high-risk pregnancies

Insights into clinical features and genetic variants of Cornelia de Lange syndrome in China

Many preschoolers with ADHD receive medication before behavioral therapy

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News